Dostarlimab|Jemperli|Structure|MOA|Dose|Uses|Side-effects

  

 Dostarlimab

Dostarlimab is an antineoplastic drug used in the treatment of endometrial cancer. The brand name of Dostarlimab is Jemperli. It is a monoclonal antibody approved on the 22nd of April 2021 by the Food and Drug Administration. It is a programmed death-1(PD1) receptor, antagonist. The molecular weight of dostarlimab is 144325.7 gm/mol. It is available for Intravenous use only.

Structure:

The molecular formula of dostarlimab is,[C­­­­­6420H₉₈₃₂N1690 O2014S44].

Mechanism of action:

The cancer cell binds with the 'T' cell with the help of the programmed death-1(PD1) receptor and PD-L1 or PD-L2 receptor interaction. Dostarlimab is a monoclonal antibody of the IgG4 isotype, which inhibits the programmed death-1(PD1) receptors on the 'T' cell. this drug blocks the interaction between the programmed death-1(PD1) receptor and the PD-L1 or PD-L2 receptor(present in the cancer cell).

Doses:

Dostarlimab is used only for adults. The usual adult dose is 500 mg intravenously once every three weeks for 10 weeks. After 10 weeks the dose is increased, to 1000 mg intravenously once every six weeks until the disease is not properly cured.

Uses:

• Dostarlimab is mainly used in the treatment of endometrial cancer. 
• Dostarlimab is also used to treat solid tumors.

Side-effects:

The overdose of dostarlimab shows different types of side effects like,

1. Urinary Tract Infections.
2. Muscle pain.
3. Nausea.
4. Vomiting.
5. Constipation.
6. Itching.
7. Anemia.
8. Weakness.
9. Diarrhea.
10. Decreased appetite.